ketamine
NDA- Indications
- Suicidal depression
Company intelligence / Profile preview
HOPE Therapeutics, Inc.
Miami, Florida, United Statesnrxpharma.com ↗
- Ownership
- Private
- Development stage
- NDA
01
Overview
HOPE Therapeutics is building a network of interventional psychiatry clinics offering treatments for suicidal depression and PTSD. The company is acquiring established clinics like Kadima Neuropsychiatry Institute to serve as clinical models for their treatment offerings nationwide.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Ketamine therapyTranscranial Magnetic Stimulation (TMS)Psychedelic medicationsNeuroplastic therapies
- Industry
- Non-Academic Healthcare
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Global medical device manufacturer (unnamed)Universal Capital, LLC
Beyond the preview
Go deeper on HOPE Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HOPE Therapeutics, Inc..